31.44 Mkt Cap: 860.20M P/E: 23.91
Pre-Market: 31.70 +0.26 (0.83%)
www.chinameditech.com
hohes Potential, derzeit von 12 Analysten nur 2 BUY, 1 strong buy, 2 neutral
China Medical Technologies, Inc. (China Medical) is a medical device company that develops, manufactures and markets products using high-intensity focused ultrasound (HIFU) for the treatment of solid cancers and benign tumors in China. As of March 31, 2006, the Company had two products. The Company's main product, the HIFU therapy system, is an ultrasound-guided acoustic ablation system that is used for the non-invasive treatment of solid tumors. Its second product, the enhanced chemiluminescence (ECLIA) system, is an enhanced chemiluminescence immunoassay in-vitro diagnostics (IVD) system that can be used to diagnose and analyze a variety of diseases and conditions, including various thyroid disorders, diabetes, hepatitis disorders related to reproduction and growth, various types of tumors, as well as to assess the effect of digoxin, a drug for the treatment of heart failure. In March 2007, the Company completed the acquisition of a fluorescent in situ hybridization (FISH) business.
Pre-Market: 31.70 +0.26 (0.83%)
www.chinameditech.com
hohes Potential, derzeit von 12 Analysten nur 2 BUY, 1 strong buy, 2 neutral
China Medical Technologies, Inc. (China Medical) is a medical device company that develops, manufactures and markets products using high-intensity focused ultrasound (HIFU) for the treatment of solid cancers and benign tumors in China. As of March 31, 2006, the Company had two products. The Company's main product, the HIFU therapy system, is an ultrasound-guided acoustic ablation system that is used for the non-invasive treatment of solid tumors. Its second product, the enhanced chemiluminescence (ECLIA) system, is an enhanced chemiluminescence immunoassay in-vitro diagnostics (IVD) system that can be used to diagnose and analyze a variety of diseases and conditions, including various thyroid disorders, diabetes, hepatitis disorders related to reproduction and growth, various types of tumors, as well as to assess the effect of digoxin, a drug for the treatment of heart failure. In March 2007, the Company completed the acquisition of a fluorescent in situ hybridization (FISH) business.
